Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum KaloBios Pharmaceuticals, Inc. KBIO

"KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company focuses on developing medicines for patients with neglected and rare diseases through innovative and responsible business models."

OTCPK:KBIO - Post Discussion

View:
Post by StudentR on Nov 23, 2015 10:07am

KBIO and ATE

Comapare the charts between KBIO and ATE.V
Looks like we have a lagger that hasent popped yet.
Last chance to get on board before the next big 10 bagger ;)
Comment by jerrio78 on Nov 23, 2015 11:22am
Although the stories are different ATE.V is probably one of the most undre valued junior in the space IMO. Phase II needs to launch so we can get people seeing this is a value story. I took a very small position in KBIO at 10 and out at 21, I think its flying a bit high now though but you cant tell the market what it likes and doesnt like. Exciting to watch still.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities